Ksenia Blinova | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Dr. Ksenia Blinova | Pharmacology | Best Researcher Award

Associate Director at US Food and Drug Administration, United States

Dr. Ksenia Blinova, Ph.D., is the Associate Director for the Division of Applied Regulatory Science at the U.S. Food and Drug Administration, where she leads innovative research, regulatory reviews, and scientific consultations that advance translational science in support of public health. With a strong academic foundation in physics, mathematics, and cardiac electrophysiology, she has built a distinguished career focused on bridging fundamental science with regulatory applications. Since joining the FDA as a Commissioner’s Fellow, Dr. Blinova has held key leadership roles, including Deputy Director of the Division of Biomedical Physics, where she led multidisciplinary teams in developing over forty regulatory science tools that improved the evaluation of medical devices across fields such as cardiology, neurostimulation, diagnostics, and patient monitoring. Her career reflects a unique combination of scientific excellence, leadership, and commitment to advancing safe and effective medical products, making her an influential figure in the field of regulatory science.

Professional Profile 

Scopus Profile | ORCID Profile 

Education

Dr. Ksenia Blinova earned her undergraduate and doctoral degrees in Physics and Mathematics from Moscow State University, where she developed a strong foundation in quantitative sciences and analytical problem-solving. She further advanced her academic journey through a postdoctoral fellowship at the National Heart, Lung, and Blood Institute at the National Institutes of Health. Her research during this period centered on cardiac electrophysiology and metabolism, areas that deepened her expertise in biomedical applications of physical sciences. This educational trajectory not only equipped her with advanced technical knowledge but also gave her a unique interdisciplinary perspective that integrates rigorous physics and mathematical methodologies with life sciences and clinical research. Her educational background has been pivotal in shaping her ability to address complex regulatory and scientific challenges, contributing to her capacity for innovation and leadership in translational science and regulatory policy at the intersection of medicine, technology, and public health.

Experience

Dr. Blinova has built a distinguished career at the U.S. Food and Drug Administration, beginning as a Commissioner’s Fellow and progressing to influential leadership roles. As Deputy Director of the Division of Biomedical Physics in the Center for Devices and Radiological Health, she guided a multidisciplinary team in creating innovative regulatory science tools that addressed critical challenges in medical device safety and effectiveness. Her leadership was instrumental in developing methods and resources for fields such as cardiology, neurostimulation, ophthalmology, in-vivo diagnostics, and advanced patient monitoring. Currently serving as Associate Director for the Division of Applied Regulatory Science in the Office of Clinical Pharmacology, she oversees research, scientific consultations, and regulatory reviews that support the FDA’s translational science priorities. Through these roles, she has combined her technical expertise with strategic vision, ensuring that scientific advancements translate into practical regulatory applications that safeguard patient health and promote medical innovation.

Research Focus

Dr. Blinova’s research focuses on advancing translational and regulatory science to accelerate the safe and effective delivery of medical products to patients. Her early work in cardiac electrophysiology and metabolism provided insights into fundamental mechanisms of heart function, laying the groundwork for her later contributions in biomedical physics and device evaluation. At the FDA, she has led research efforts that integrate computational modeling, experimental studies, and regulatory tool development to address complex safety and efficacy challenges in medical devices and drug-device combinations. Her team has developed innovative approaches to evaluate technologies in cardiology, neurostimulation, electrical safety, diagnostics, and patient monitoring, ensuring that regulatory science keeps pace with rapid technological advances. By bridging basic science, applied research, and policy, her work exemplifies the role of regulatory science in translating innovation into tangible benefits for patients and healthcare systems, while maintaining a focus on safety, effectiveness, and public health impact.

Award and Honor

Throughout her career, Dr. Blinova has been recognized for her leadership, innovation, and contributions to regulatory science. Her accomplishments include guiding the development of over forty regulatory tools that have had a lasting impact on how medical devices are assessed for safety and effectiveness. These achievements reflect not only her scientific expertise but also her ability to collaborate across disciplines to solve pressing healthcare challenges. Her recognition within the FDA and broader scientific community underscores her role as a leader who consistently advances the field of translational science. Honors and awards in her career highlight her success in bridging science and regulation, her dedication to patient safety, and her influence in shaping modern approaches to medical product evaluation. These distinctions serve as a testament to her sustained contributions, her commitment to innovation, and her growing impact as a respected figure in regulatory and biomedical research.

Publication Top Notes

  • Title: Nonclinical Human Cardiac New Approach Methodologies (NAMs) Predict Vanoxerine-Induced Proarrhythmic Potential
    Authors: M. Iveth Garcia, Bhavya Bhardwaj, Keri Dame, Verena Charwat, Brian A. Siemons, Ishan Goswami, Omnia A. Ismaiel, Sabyasachy Mistry, Tromondae K. Feaster, Kevin E. Healy, et al.
    Year: 2025

  • Title: In Vitro Assay Development to Study Pulse Field Ablation Outcome Using Solanum Tuberosum
    Authors: Akshay Narkar, Abouzar Kaboudian, Yasaman Ardeshirpour, Maura Casciola, Tromondae Feaster, Ksenia Blinova
    Year: 2024
    Citations: 2

  • Title: Nonclinical evaluation of chronic cardiac contractility modulation on 3D human engineered cardiac tissues
    Authors: Tromondae K. Feaster, Jourdan K. Ewoldt, Anna Avila, Maura Casciola, Akshay Narkar, Christopher S. Chen, Ksenia Blinova
    Year: 2024

  • Title: Comprehensive Collection of Current Methods for Contractility and Electrophysiology Recordings in Human Cardiac Cells
    Authors: Ksenia Blinova, J. Pierson, A. Narkar
    Year: 2023

  • Title: Human in vitro assay for irreversible electroporation cardiac ablation
    Authors: Maura Casciola, Tromondae K. Feaster, M. J. Caiola, D. Keck, Ksenia Blinova
    Year: 2023

  • Title: Acute effects of cardiac contractility modulation stimulation in conventional 2D and 3D human induced pluripotent stem cell-derived cardiomyocyte models
    Authors: Tromondae K. Feaster, N. Feric, I. Pallotta, A. Narkar, M. Casciola, M. P. Graziano, R. Aschar-Sobbi, Ksenia Blinova
    Year: 2022

  • Title: Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
    Authors: Tromondae K. Feaster, Maura Casciola, Akshay Narkar, Ksenia Blinova
    Year: 2022

  • Title: Human in vitro neurocardiac coculture (iv NCC) assay development for evaluating cardiac contractility modulation
    Authors: Akshay Narkar, Tromondae K. Feaster, Maura Casciola, Ksenia Blinova
    Year: 2022

  • Title: Human cardiomyocytes are more susceptible to irreversible electroporation by pulsed electric field than human esophageal cells
    Authors: Maura Casciola, Devin Keck, Tromondae K. Feaster, Ksenia Blinova
    Year: 2022

  • Title: Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs)
    Authors: Akshay Narkar, James M. Willard, Ksenia Blinova
    Year: 2022

  • Title: Cardiovascular medical devices: Regulatory science research overview in the office of science and engineering laboratories (OSEL) at the food and drug administration (FDA)
    Authors: K. Aycock, Ksenia Blinova, M. Casciola, B. Craven, M. Di Prima, G. D’Souza, N. Duraiswamy, M. Farahmand, P. Hariharan, L. Herbertson, et al.
    Year: 2021

  • Title: Acute effects of cardiac contractility modulation on human induced pluripotent stem cell–derived cardiomyocytes
    Authors: Tromondae K. Feaster, Maura Casciola, Akshay Narkar, Ksenia Blinova
    Year: 2021

Conclusion

Dr. Ksenia Blinova has demonstrated exceptional expertise and leadership in translational and regulatory science, particularly in the evaluation and development of cardiac therapies and medical devices. Her extensive body of research, including numerous high-impact publications on human in vitro cardiac models, contractility modulation, and electroporation assays, reflects a consistent focus on innovative approaches that bridge fundamental science with practical clinical and regulatory applications. She has led multidisciplinary teams to develop tools and methodologies that enhance patient safety, accelerate medical innovation, and provide reliable scientific evidence for regulatory decisions. Her work not only advances the understanding of cardiac electrophysiology and device performance but also sets new standards for predictive, nonclinical cardiac research. Overall, Dr. Blinova’s contributions exemplify the qualities of a pioneering researcher whose scientific rigor, leadership, and commitment to public health make her highly deserving of recognition in any Best Researcher Award.

Franciska Erdő | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on by World Top Scientists

Prof. Dr. Franciska Erdő | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

full professor at Pázmány Péter Catholic University, Hungary

Franciska Vidáné Dr. Erdő is a distinguished researcher and professor in drug research and development, with extensive experience in academia and the pharmaceutical industry. Born on May 28, 1964, in Budapest, Hungary, she has contributed significantly to pharmacology, drug delivery, and biomedical research. Over her career, she has held leadership roles in prestigious institutions across Hungary, Germany, and France. As a full professor and lab head at Pázmány Péter Catholic University, she plays a key role in advancing scientific knowledge. Her research has been widely recognized, earning her multiple fellowships and memberships in international scientific societies. Dr. Erdő has supervised numerous students, organized international scientific meetings, and served as a reviewer for high-impact journals. She is also actively involved in grant evaluation for major research funding agencies in Europe, further establishing her as a leading expert in her field.

Professional Profile

Education

Dr. Erdő’s academic journey is rooted in pharmaceutical sciences. She obtained her MSc in Pharmacy from Semmelweis University, Faculty of Pharmacy, in 1987 with excellent distinction. She continued her studies at the same institution, earning her University Doctor title in pharmacology in 1994, followed by a PhD in 1997, both summa cum laude. To further enhance her expertise, she pursued a habilitation at Pázmány Péter Catholic University in 2019, ultimately achieving the title of full professor in 2024. Additionally, she has undertaken specialized training, including EU grant writing and experimental animal research under new EU regulations. Her diverse educational background has enabled her to excel in drug development, pharmacology, and biotechnology, equipping her with a strong foundation to lead innovative research in these fields.

Professional Experience

Dr. Erdő’s professional career spans more than three decades, encompassing roles in academia, research institutes, and the pharmaceutical industry. She has held various research fellow and senior research fellow positions in leading institutions such as Sanofi-Synthelabo Chinoin, IVAX Drug Research Institute, and SOLVO Biotechnology. Between 2000 and 2003, she was a Max Planck Fellow at the Max-Planck Institute in Germany, furthering her expertise in neurological research. She has also worked as a scientific researcher at Charité Medical University in Berlin. Since 2014, she has been an integral part of Pázmány Péter Catholic University, where she has progressed from senior research fellow to full professor and lab head. Her leadership in drug research and development, coupled with her extensive collaborations with international institutions, has significantly contributed to the advancement of pharmaceutical sciences.

Research Interests

Dr. Erdő’s research focuses on drug delivery across physiological barriers, including the skin, blood-brain barrier, and mucosal tissues. Her studies explore transdermal and intranasal drug administration, pharmacokinetics, and tissue engineering. She has contributed to the development of lab-on-a-chip models for drug testing, providing innovative solutions for pharmaceutical research. Her interdisciplinary approach combines pharmacology, biomedical engineering, and nanotechnology to improve drug formulation and delivery methods. She has authored numerous high-impact publications on skin permeability, microfluidic diffusion chambers, and age-related changes in drug absorption. Her research also includes in vitro and ex vivo studies on skin-on-a-chip platforms, contributing to advancements in personalized medicine. Dr. Erdő’s work has gained international recognition, shaping the future of drug development and targeted therapy solutions.

Awards and Honors

Dr. Erdő has been the recipient of numerous prestigious awards and fellowships throughout her career. She was a Max Planck Fellow from 2000 to 2003, a Charité Medical University Scholar in 2006, and a recipient of the LE STUDIUM Fellowship in 2022 under the Smart Loire Valley program in France. Her excellence in teaching and research has been recognized through multiple Teaching-Research Excellence Scholarships at Pázmány Péter Catholic University. She has also received publication fellowships for her outstanding contributions to scientific literature. Additionally, she plays a crucial role as a grant evaluator for the EU’s Horizon programs, the Austrian Science Fund, and other major research funding agencies. Her achievements highlight her significant impact on the global scientific community, reinforcing her reputation as a leading expert in pharmaceutical and biomedical research.

Conclusion

Dr. Franciska Vidáné Erdő is a highly suitable candidate for the Best Researcher Award due to her outstanding contributions to drug research, mentorship, and international collaborations. Her extensive publication record, leadership in scientific organizations, and impact on pharmacology and biomedical sciences make her a strong contender. Enhancing industry engagement and public science communication could further solidify her position as a top researcher.

Publications Top Noted

1. In Vitro Functional and Structural Evaluation of Low-Complexity Artificial Human Epidermis for 3D Tissue Engineering

  • Author: Erdő F., et al.
  • Year: 2025
  • Journal: Bioengineering
  • DOI: 10.3390/bioengineering12030230

2. Fluid Dynamics Optimization of Microfluidic Diffusion Systems for Assessment of Transdermal Drug Delivery: An Experimental and Simulation Study

3. Progress in Topical and Transdermal Drug Delivery Research—Focus on Nanoformulations

4. Mathematical Modeling of Transdermal Delivery of Topical Drug Formulations in a Dynamic Microfluidic Diffusion Chamber in Health and Disease

5. Rodent Models of Dermatological Disorders

6. Models for Barrier Understanding in Health and Disease in Lab-on-a-Chips

7. Transdermal Delivery of α-Aminophosphonates as Semisolid Formulations—An In Vitro-Ex Vivo Study

8. Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)-In Vitro Testing

9. Editorial: Women in Drug Metabolism and Transport: 2021

10. Structural and Functional Analysis of Excised Skins and Human Reconstructed Epidermis with Confocal Raman Spectroscopy and in Microfluidic Diffusion Chambers

11. Novel Aspects of Raman Spectroscopy in Skin Research

  • Author: Erdő F., et al.
  • Year: 2022
  • Journal: Experimental Dermatology
  • DOI: 10.1111/exd.14645

12. Characterization and Ex Vivo Evaluation of Excised Skin Samples as Substitutes for Human Dermal Barrier in Pharmaceutical and Dermatological Studies

  • Author: Erdő F., et al.
  • Year: 2022
  • Journal: Skin Research and Technology
  • DOI: 10.1111/srt.13165

13. Drug Delivery through the Psoriatic Epidermal Barrier—A “Skin-On-A-Chip” Permeability Study and Ex Vivo Optical Imaging

  • Author: Erdő F., et al.
  • Year: 2022
  • Journal: International Journal of Molecular Sciences
  • DOI: 10.3390/ijms23084237

14. Skin-on-a-Chip Technology for Testing Transdermal Drug Delivery—Starting Points and Recent Developments

15. Age-Related Inflammatory Balance Shift, Nasal Barrier Function, and Cerebro-Morphological Status in Healthy and Diseased Rodents